Breast Cancer Research and Treatment最新文献

{"title":"Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution.","authors":"Emily L Chen, Hillary Heiling, Tianyu Li, Jennifer R Bellon, Faina Nakhlis, Heather A Parsons, Alyssa Martin, Harold J Burstein, Sara M Tolaney, Craig Snow, Nabihah Tayob, Lior Z Braunstein, Nancy U Lin, Sarah Sammons","doi":"10.1007/s10549-025-07889-y","DOIUrl":"10.1007/s10549-025-07889-y","url":null,"abstract":"<p><strong>Purpose: </strong>De novo oligometastatic breast cancer (OMBC) is often defined as up to five metastases in two or fewer organs at presentation. Studies have suggested favorable outcomes for patients with OMBC; however, management remains controversial. We analyzed outcomes of patients with de novo OMBC treated with physician-expressed curative intent at a single institution.</p><p><strong>Methods: </strong>We identified patients by performing a keyword search for terms of interest within institutional electronic medical records. We defined OMBC as four or fewer metastases in one organ. Primary surgery was required for inclusion in the analytic cohort. Recurrence-free survival (RFS) and overall survival (OS) were evaluated using Kaplan-Meier methods.</p><p><strong>Results: </strong>Thirty-nine patients were identified: 12 hormone receptor-positive (HR+)/HER2+ , 2 HR-negative (HR-)/HER2-, 21 HR+ /HER2-, and 4 HR-/HER2+ . Thirty-three patients (84.6%) had 1 metastasis at diagnosis. Median age was 47 years (28-69). Twenty-nine patients (74.4%) underwent adjuvant radiation to the breast. Two-thirds of patients underwent metastasis-directed therapy. Five-year OS was 77% (95% CI 61-95%). Median RFS was 7.1 years (95% CI 4.62-not reached). Five-year RFS was 58% (95% CI 42-81%).</p><p><strong>Conclusions: </strong>Survival outcomes were favorable among this select cohort. Optimal treatment for de novo OMBC remains unclear. Curative intent trials are underway for HER2+ de novo OMBC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"55"},"PeriodicalIF":3.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently.","authors":"S Hjorth, K F Vandraas, C B Trewin-Nybråten, E Botteri, G Ursin, B K Andreassen, N C Støer","doi":"10.1007/s10549-025-07888-z","DOIUrl":"10.1007/s10549-025-07888-z","url":null,"abstract":"<p><strong>Purpose: </strong>Targeted therapies have improved survival in human epidermal growth factor receptor 2 positive breast cancer (HER2 + BC). However, patients over 75 years of age are often excluded from clinical trials of anti-HER2 therapies, and it is unclear to what extent they receive these treatments in routine care. To address this, we examined age-related patterns of anti-HER2 therapy use in real-world clinical practice in Norway.</p><p><strong>Methods: </strong>In a nationwide registry-based cohort, we identified women diagnosed with stage I-III HER2 + BC during 2012-2021. We investigated treatment patterns using descriptive statistics and estimated the direct effect of age on anti-HER2 therapy use by Poisson regression.</p><p><strong>Results: </strong>Among 3526 women with HER2 + BC, anti-HER2 therapy use was consistently high (83-95%) in those under 75 years, decreased to 60% at ages 75-79, and declined further with advancing age to 8% at ≥ 90 years. Neoadjuvant anti-HER2 therapy also decreased with age (from 24% in patients under 75 to 12% in patients over 75 years). Accounting for cancer characteristics, comorbidities, polypharmacy, and socio-economic factors, older patients had reduced likelihood of receiving any anti-HER2 therapy compared with patients younger than 55 (RR 0.75, 95% CI 0.66-0.85, p < 0.001, at age 75-84 and RR 0.21, 95% CI 0.11-0.41, p < 0.001, at age 85 +).</p><p><strong>Conclusions: </strong>Anti-HER2 therapy use declined substantially after the age of 75 even when accounting for comorbidities and polypharmacy. Chronological age appears important in planning treatment for patients with HER2 + BC. Specific guidelines pertaining to older patients with HER2 + BC are needed to avoid potential undertreatment.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"54"},"PeriodicalIF":3.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression.","authors":"Sihua Liu, Beidi Du, Mengmeng Zhang, Duanyang Zhai, Xutu Zhao, Nan Shao, Xiaying Kuang, Yunjian Zhang, Yawei Shi, Liang Yu, Ying Lin","doi":"10.1007/s10549-025-07885-2","DOIUrl":"10.1007/s10549-025-07885-2","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the prognosis and endocrine therapy (ET) efficacy in patients with estrogen receptor (ER)-low breast cancer.</p><p><strong>Methods: </strong>This retrospective cohort study included patients diagnosed with early-stage breast cancer at a single institution in China from January 2010 to December 2020. Clinicopathological features, survival outcomes, and the effect of ET were compared among patients with ER-low, ER-high, and ER-negative breast cancer. Analyses were stratified by human epidermal growth factor receptor 2 (HER2) status (positive or negative).</p><p><strong>Results: </strong>A total of 2951 patients were included, consisting of 131 (4.4%) ER-low, 2040 (69.1%) ER-high, and 780 (26.4%) ER-negative patients. In the HER2-negative subgroup, ER-low patients had significantly worse breast cancer-free survival (BCFS) (P = 0.016) and a higher risk of locoregional recurrence (P < 0.001) compared to ER-high patients, while no significant differences were observed in prognosis between ER-low and ER-negative patients. In the HER2-positive subgroup, there were no significant differences in prognosis among patients with different ER expression levels. ET could significantly reduce the risk of locoregional recurrence and distant metastasis and significantly improve BCFS for ER-low patients, especially in the HER2-negative subgroup. However, in the HER2-positive subgroup, ET did not improve BCFS or overall survival for ER-low patients.</p><p><strong>Conclusion: </strong>HER2-negative/ER-low breast cancer has a similar clinical behavior to triple-negative breast cancer, and ET could significantly reduce the risk of recurrence and metastasis for this subgroup. However, in HER2-positive patients, ER-low breast cancer lacks a predictive role in prognosis and derives no clear benefit from ET.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"51"},"PeriodicalIF":3.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in compliance with cardiovascular medication after a breast cancer diagnosis: a latent class trajectory analysis using French nationwide data.","authors":"Juliette Artignan, Perrine Capmas, Henri Panjo, Daniel Bejarano-Quisoboni, Nathalie Pelletier-Fleury","doi":"10.1007/s10549-025-07882-5","DOIUrl":"10.1007/s10549-025-07882-5","url":null,"abstract":"<p><strong>Background: </strong>Managing cardiovascular risk is key for breast cancer survivors, many of whom have pre-existing conditions like hypertension and hyperlipidaemia. Research suggests compliance with cardiovascular medication declines after a breast cancer diagnosis. However, these studies rely on population-level averages, which mask patient heterogeneity and longitudinal variations in compliance. This study aimed to identify compliance trajectories with cardiovascular medication around a breast cancer diagnosis and describe associated characteristics.</p><p><strong>Methods: </strong>Using the French National Health Data System, we constructed a cohort of women diagnosed with incident breast cancer (2016-2020) who received at least 2 cardiovascular drug classes before diagnosis for primary prevention, defined as treatment of cardiovascular risk factors in the absence of established cardiovascular disease. Compliance trajectories were analysed over 3 years using group-based trajectory modelling.</p><p><strong>Results: </strong>Among 35,399 women, 6 trajectories were identified: stable high compliance (49.9%), moderate stable (21.2%), low stable (12.8%), sharp decline post-diagnosis (9.8%), treatment discontinuation post-diagnosis (3.4%), and very low and declining (2.9%). Declining trajectories were associated with higher rates of metastases and chemotherapy.</p><p><strong>Conclusion: </strong>This study revealed substantial heterogeneity in compliance responses post-diagnosis. While most women maintained stable compliance, a significant subset experienced sharp declines, likely linked to cancer severity. Early interventions post-diagnosis could reduce cardiovascular risk and improve outcomes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"52"},"PeriodicalIF":3.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.","authors":"William M Tahaney, Amanda Lanier, Jing Qian, Cassandra L Moyer, Nghi Nguyen, Yanxia Ma, Jamal Hill, Reid T Powell, Clifford C Stephan, Peter J A Davies, Abhijit Mazumdar, Powel H Brown","doi":"10.1007/s10549-025-07865-6","DOIUrl":"10.1007/s10549-025-07865-6","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high rates of tumor protein 53 (TP53) mutation and with limited targeted therapies. Despite being clinically advantageous, direct targeting of mutant TP53 has been challenging. Therefore, we hypothesized that p53-mutant TNBC cells rely upon other potentially targetable survival pathways.</p><p><strong>Methods: </strong>In vitro and in silico screens were used to identify drugs that induced preferential death in TP53-mutant cells. The effect of the ferroptosis inducer ML-162 was tested both in vitro and in vivo and the mechanism of cell death following ML-162 treatment or GPX4 knockout was determined.</p><p><strong>Results: </strong>High-throughput drug screening demonstrated that TP53-mutant TNBCs are highly sensitive to peroxidase, cell cycle, cell division, and proteasome inhibitors. We further characterized the effect of the ferroptosis inducer ML-162 and demonstrated that ML-162 induces preferential ferroptosis in TP53-mutant TNBC cells. Treatment of TP53-mutant xenografts with ML-162 suppressed tumor growth and increased lipid peroxidation in vivo. Testing ferroptosis inducers demonstrated TP53-missense mutant, and not TP53-null or wild-type cells, were more sensitive to ferroptosis, and expression of mutant TP53 genes in p53-null cells sensitized cells to ML-162 treatment.</p><p><strong>Conclusions: </strong>This study demonstrates that TP53-mutant TNBC cells have unique survival pathways that can be effectively targeted. Our results illustrate the intrinsic vulnerability of TP53-mutant TNBCs to ferroptosis and highlight GPX4 as a potential target for the precision treatment of TP53-mutant TNBC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"49"},"PeriodicalIF":3.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RISE UP for breast cancer 2024: conference highlights & takeaways.","authors":"Taylor Glatt, Katherine Leggat-Barr, Nandini Seth, Diane Heditsian, Laura van 't Veer, Lajos Pusztai, Elissa Price, Nola Hylton, Silvia Formenti, Hope Rugo, Laura Fejerman, Adetunji T Toriola, Carol Fabian, Andrea De Censi, Daniel Grossman, Olufunmilayo Olopade, Andrea Jackson, Sara Horton, Kim Rhoads, Carol Lange, Virginia Borges, Elizabeth Garner, Judy Garber, Douglas Yee, Laura Esserman","doi":"10.1007/s10549-025-07848-7","DOIUrl":"10.1007/s10549-025-07848-7","url":null,"abstract":"<p><p>RISE UP (Revolutionizing Investigations to StEp Up Prevention) for breast cancer brought together leading cancer specialists, women's health providers, basic and population scientists, regulators, politicians, industry leaders, patient advocates, and more from around the world to discuss and chart a radical rethinking of breast cancer prevention and risk reduction through a lens of hormonal management across a woman's life course. The presentations at RISE UP were organized to outline a path forward by leveraging what we know about breast cancer biology, early detection, treatment, and endocrine therapy toward a better and sustainable approach for breast cancer prevention. Important conference considerations were to expand our thinking about prevention by broadly considering how the hormonal environment during different life phases or common benign conditions could be better managed to minimize breast cancer risk. This set the stage for transitioning to advances in risk prediction, promising risk-reducing agents, and biomarker-driven trials to test them. Biomarker-based trials discussed focused on 1) lower or intermittent doses of standard prevention agents, 2) drugs already approved for other health purposes, and 3) maximizing benefits from lifestyle interventions alone or in combination. Throughout RISE UP, there was a strong focus on promoting health equity, including comprehensive reproductive health access, equitable representation in clinical trials, and strategies to educate women, providers, and advocates about disparities in care and how to successfully reduce them. The meeting concluded with a competition for innovative approaches to breast cancer prevention that could be integrated into hormonal and women's health interventions. RISE UP was an innovative conference that provided a forum for cross-cutting topics in women's health that do not currently exist. The insights shared at RISE UP will be paradigm shifting in breast cancer prevention and women's health space in the years to come.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"53"},"PeriodicalIF":3.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of second non-breast primary cancer in Chinese breast cancer patients with germline BRCA1/2 pathogenic variants.","authors":"Jiaming Liu, Futao Chu, Lu Yao, Jie Sun, Jiuan Chen, Juan Zhang, Ye Xu, Yuntao Xie","doi":"10.1007/s10549-025-07886-1","DOIUrl":"10.1007/s10549-025-07886-1","url":null,"abstract":"<p><strong>Purpose: </strong>The risk of second non-breast primary cancer in Chinese women with breast cancer who carry germline BRCA1/2 pathogenic variants (PVs) is largely unknown.</p><p><strong>Methods: </strong>From October 2003 to February 2023, 11,212 women with breast cancer were recruited. BRCA1/2 mutation status of these patients was determined; the age-specific cumulative risk of second non-breast primary cancer was estimated.</p><p><strong>Results: </strong>Of the 11,212 breast cancer patients, 284 carried BRCA1 PVs, 433 carried BRCA2 PVs, and 10,495 were non-carriers. After a median follow-up of 8.4 years, 10.9% of BRCA1 carriers, 7.2% of BRCA2 carriers, and 3.6% of non-carriers developed second non-breast primary cancers; and 6.7% of BRCA1 carriers, 1.4% of BRCA2 carriers, and 0.1% of non-carriers developed ovarian cancer. Cumulative risks of second primary cancer to age 70 years were 28.4% for BRCA1 carriers, 17.3% for BRCA2 carriers, and 6.2% for non-carriers. Cumulative risks of ovarian cancer to age 70 years were 19.8% for BRCA1 carriers, 3.9% for BRCA2 carriers, and 0.4% for non-carriers. No BRCA1 and BRCA2 carriers developed ovarian cancer before the ages of 40 and 45 years, respectively. BRCA2 carriers had higher risks of thyroid cancer (relative risk [RR] 2.16; 95% CI, 1.04-4.51; P = 0.039) and endometrial adenocarcinoma (RR 3.90; 95% CI, 1.47-10.32; P = 0.006) than non-carriers.</p><p><strong>Conclusions: </strong>BRCA1/2 carriers exhibit a 2- to 3-fold higher risk of second primary cancer than non-carriers. Ovarian cancer represents the majority of second primary cancers in BRCA1 carriers, while BRCA2 carriers have a wider spectrum of second primary cancers.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"50"},"PeriodicalIF":3.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145909907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing barriers to genomic testing in breast cancer among diverse patients: a qualitative community-engaged research study.","authors":"Mary U O Olomu, Casey Scherer, Emily Wood, Kasandra Escobar, Sacha Moufarrej, Rafaay Kamran, Shannon Muir, Fatima Muñoz, Mariana Stern, Scarlett Gomez, Douglas W Blayney, Helen Chew, Lisa M Tealer, Amy Alanes, Dolores Moorehead, Mayte Sanchez, Keily Becerra Sánchez, Stacey Tinianov, Ysabel Duron, Manali I Patel","doi":"10.1007/s10549-025-07871-8","DOIUrl":"10.1007/s10549-025-07871-8","url":null,"abstract":"<p><strong>Purpose: </strong>Genomic testing informs treatment decisions for estrogen receptor-positive, progesterone receptor-positive, and HER2-negative early-stage breast cancer, yet uptake remains disproportionately low among racially and ethnically minoritized and low-income populations. Understanding the multilevel barriers driving these disparities is essential for equitable delivery of personalized cancer care. This study explores barriers to and potential solutions for equitable access to genomic testing, incorporating perspectives from patients, caregivers, clinicians, navigators, payers, and policymakers.</p><p><strong>Methods: </strong>We conducted a qualitative study using community-based participatory research principles in partnership with five community-based organizations. Semi-structured interviews were completed with 32 participants: patients (n = 20), caregivers (n = 2), clinicians (n = 4), navigators (n = 2), payers (n = 2), and policymakers (n = 2). Transcripts were analyzed using constructivist grounded theory and interpretive description.</p><p><strong>Results: </strong>Three major themes emerged: (1) Limited awareness and information across interested groups, including confusion between genomic and genetic testing, particularly among patients, caregivers, and some healthcare staff; (2) Modifiable challenges in accessing genomic testing, such as administrative complexity, insurance barriers, and financial toxicity; and (3) Racial, ethnic, and socioeconomic factors, including language barriers and lack of culturally appropriate materials, that impede equitable access to testing.</p><p><strong>Conclusions: </strong>Equitable delivery of genomic testing in breast cancer requires multilevel interventions targeting structural barriers, administrative complexity, and culturally tailored education. Addressing these barriers is likely to reduce disparities and further improve health equity in cancer care.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"47"},"PeriodicalIF":3.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of breast cancer treatment on sleep disturbance: a systematic review.","authors":"Emma-Kate Carson, Haryana M Dhillon, Janette L Vardy, Chris Brown, Claire Mok, Alisha Panambalana, Belinda E Kiely","doi":"10.1007/s10549-025-07835-y","DOIUrl":"10.1007/s10549-025-07835-y","url":null,"abstract":"<p><strong>Background: </strong>People receiving treatment for breast cancer often report sleep disturbance. This systematic review explored the prevalence and impact of breast cancer treatment on sleep disturbance.</p><p><strong>Methods: </strong>The Medline, Embase, CINAHL Plus with full text, Psych INFO, Cochrane Library/Central Register of Controlled Trials, and Scopus databases were searched up to December 2024. Eligible studies recruited people undergoing breast cancer treatment and reported the impact of treatment on their sleep. Two authors reviewed full-text publications for eligibility, data extraction, and quality appraisal. Demographics and sleep outcomes were summarised via descriptive statistics.</p><p><strong>Results: </strong>Among the 32,119 studies identified, 80 met the eligibility criteria. Studies have used a variety of sleep assessment measures and thresholds to define sleep disturbance. The Pittsburgh Sleep Quality Index (PSQI) and actigraphy were the most frequently used, 63% and 24%, respectively. The mean prevalence of poor sleep quality (as per the PSQI) for each treatment was as follows: surgery, 63%; chemotherapy, 62%; radiation therapy, 64%; and endocrine therapy, 57%; and clinically significant insomnia (as per the Insomnia Severity Index) for surgery, 20%; chemotherapy, 24%; radiation therapy, 23%; and endocrine therapy, 35%. A significant increase in sleep disturbance related to cancer treatment was reported in 62% of the studies assessing chemotherapy, 39% assessing radiation therapy, 20% assessing endocrine therapy, and 17% assessing breast surgery.</p><p><strong>Conclusion: </strong>Sleep disturbance is reported in approximately 60% of people receiving treatment for breast cancer, with chemotherapy being the most studied treatment. The prevalence and severity of sleep disturbance vary across studies due to the heterogeneity of assessment tools used, and thresholds to define poor sleep. This highlights the need for a consistent method of assessing sleep disturbance and the need for effective strategies to improve sleep.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"48"},"PeriodicalIF":3.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor biology and access to care and metastatic breast cancer outcomes.","authors":"Matthew R Dunn, Sarah C Van Alsten, Marc A Emerson, Katherine Reeder-Hayes, Terry Hyslop, Melissa A Troester","doi":"10.1007/s10549-025-07881-6","DOIUrl":"10.1007/s10549-025-07881-6","url":null,"abstract":"<p><strong>Purpose: </strong>To understand how access to care influences metastatic breast cancer burden (MBC) while accounting for molecular tumor characteristics, and identify interventions to reduce metastatic disease burden.</p><p><strong>Methods: </strong>The Carolina Breast Cancer Study is a population-based cohort with invasive breast cancer (diagnosed 2008-2013). Both de novo metastasis (stage IV at diagnosis) and distant recurrence were evaluated (12 years of follow-up. Tumor data were from medical records, pathology reports, and RNA expression data. Social variables and access to care were from participant surveys. Generalized linear models were used to estimate associations of biological and access characteristics with MBC; Cox models were used to estimate recurrence hazards.</p><p><strong>Results: </strong>464/2998 patients (15.5%) had MBC (n = 109 de novo; n = 355 recurrent). MBC was associated with grade 3 vs 1 (odds ratio (OR) = 4.15, 95% CI: 2.60, 6.99), LumB vs LumA (OR = 2.08, 95% CI: 1.48, 2.90), and high vs low PAM50 risk of recurrence score (OR = 4.45, 95% CI: 2.93, 6.99) vs. non-MBC. MBC was associated with Black race (Hazard ratio (HR) = 1.66, 95% CI: 1.32, 2.11), poverty (HR = 1.47; 95% CI: 1.09, 1.99), and low education (HR = 1.48, 95% CI: 1.03, 2.13). Controlling for healthcare access (screening, regular care, delayed treatment, and community healthcare) attenuated associations with metastasis for poverty and education, but had lesser effects on race associations.</p><p><strong>Conclusions: </strong>Disparities in MBC burden persist after adjustment for individual- and community-level healthcare access. Reducing burden of MBC in Black women necessitates simultaneous targeting of biological and access to care factors.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"46"},"PeriodicalIF":3.0,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12743023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}